Live Biotherapeutic Products And Microbiome CDMO Market To Reach $397.49 Million By 2030

Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends

The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 397.49 million by 2030, expanding at a CAGR of 38.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.

Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology’s 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

 Request a free sample copy or view report summary: Live Biotherapeutic Products And Microbiome CDMO Market Report

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights

• C.difficle held the largest revenue share in 2024 owing to the increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the live biotherapeutic products and microbiome contract development and manufacturing market.

• Many companies focus on developing and manufacturing products for treating C.difficle infections, driving the market's expansion.

• North America live biotherapeutic products and microbiome CDMO market accounted for the largest share of 76.84% in 2024 of the global live biotherapeutic products and microbiome market.

• Asia Pacific is expected to grow at a CAGR of 44.82% during the forecast period. The market in Asia Pacific has witnessed significant growth and promising developments in recent years.

Live Biotherapeutic Products And Microbiome CDMO Market Segmentation

Grand View Research has segmented the global live biotherapeutic products and microbiome CDMO market report based on application, and region:     

Live Biotherapeutic Products And Microbiome CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)

• C. Difficle

• Crohn’s Disease

• IBS

• Diabetes

• Others

Live Biotherapeutic Products And Microbiome CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Live Biotherapeutic Products And Microbiome CDMO Market

• Arrant Bio

• 4D Pharma

• Cerbios

• Biose Industrie

• Assembly Biosciences, Inc.

• Wacker Chemie AG

• Quay Pharmaceuticals

• NIZO

• Lonza

• Inpac Probiotics